BioSpace News Archive

ChemDiv Inc, a global leader in drug discovery and drug development solutions, shares the progress in the development of its cutting-edge biology facility at Biocant Park, Cantanhede, Portugal.

Elevation Oncology, Inc. (Nasdaq: ELEV) today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating EO-3021 in patients with advanced unresectable or metastatic solid tumors likely to express Claudin 18.2 including gastric, gastroesophageal junction, pancreatic or esophageal cancers.

Cidara Therapeutics, Inc. today announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development.

Empress Therapeutics Appoints Dawn Thompson, Ph.D., Senior Vice President, Head of Platform Development.

Seagen Phase 3 Trial of TUKYSA ® (tucatinib) in Combination with Antibody-Drug Conjugate ado-trastuzumab emtansine Meets Primary Endpoint of Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer.

Functional Fluidics, a US-based biotechnology company, proudly announces its global expansion into Africa in the fourth quarter of 2023.

More than one-third of health system executives participating in a recent survey are planning to automate two or more revenue cycle management (RCM) or finance functions in 2024, according to a report published by the Healthcare Financial Management Association (HFMA) and Eliciting Insights, a healthcare strategy and market research company.

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”) today announced that additional NXC-201 clinical data for relapsed/refractory AL Amyloidosis has been selected for oral presentation at the 20th International Myeloma Society Annual Meeting to be held in Athens, Greece, September 27-30, 2023.

Tivic Health® Systems, Inc. announced that the research study that the company is funding at The Feinstein Institutes for Medical Research has received study approval from the Institutional Review Board and has initiated study recruitment and enrollment for its novel non-invasive bioelectronic device approach to vagus nerve stimulation.

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ (CMS) Molecular Diagnostics Services Program (MolDX).